Evidence map›Paper›PMID 41658617›Full record

ArticleFrontiers in medicine2026

A simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis.

Yuteng Yang, Tingyang Wei, Shuo Yang, Ran Fei, Changjie Tie, Rui Han, Danli Ma, Qian Jin, Jian Wang, Zixing Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuteng Yang *Peking University People's Hospital, Beijing, China.
Tingyang Wei *Peking University People's Hospital, Beijing, China.
Shuo Yang *Department of Radiology, Peking University People's Hospital, Beijing, China.
Ran Fei *Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People's Hospital, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Changjie TiePeking University People's Hospital, Beijing, China.
Rui HanDepartment of Internal Medicine, Harbin Pingfang District People's Hospital, Harbin, China.
Danli MaBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People's Hospital, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Qian JinBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People's Hospital, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Jian WangBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People's Hospital, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Zixing WangBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People's Hospital, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Rui HuangBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People's Hospital, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the predictors and prognostic impact of sarcopenic obesity (Sa-O) on all-cause mortality in patients with cirrhosis. Methods: This retrospective cohort study included cirrhosis patients. Sa-O was defined using computed tomography at L3 level as a skeletal muscle index <42 cm Results: Among 769 cirrhosis patients (60.1% male; 45.5% aged ≥60 years; median follow-up: 4.3 [1.7-7.0] years), 129 (16.8%) were diagnosed with Sa-O. Multivariable analysis identified age (OR [odds ratio] 1.813, 95% confidence interval [CI] 1.210-2.718, Conclusion: Sa-O in patients with cirrhosis is associated with age, BMI, alcoholic liver disease, and hypertension. The newly developed ABAH score, a composite clinical risk marker, predicted the probability of Sa-O and was associated with all-cause mortality in patients with cirrhosis.

Indexed as

body compositioncomputed tomographyliver cirrhosisprognosissarcopenic obesity

Identifiers

PMID41658617
PMCPMC12872800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.